Shire Adderal/Dextrostat
Executive Summary
Explosion in pharmaceutical manufacturer Arenol's Sommerville, N.J. facility endangers supply of Adderall and Dextrostat, Shire's products for the treatment of attention deficit/hyperactivity disorder. Shire will either restart manufacturing at Arenol or transfer agreements to an alternative facility. Shire predicts sufficient supply for the next 3-4 months, but does not expect to re-establish a source of active ingredient before the exhaustion of currently available stocks. The supply halt will likely have an adverse effect on Shire's financial condition, as Adderall and Dextrostat represented 63% of Shire's revenue in the six months ended June 30